Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT02469090
- Locations
- 🇨🇦
UHN Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸Emory University Department of Neurology, Atlanta, Georgia, United States
🇺🇸The Research Center of Southern California, Oceanside, California, United States
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02467361
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Dasotraline Pediatric Extension Study
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02457819
- Locations
- 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸Harmonex Neuroscience Research, Inc, Dothan, Alabama, United States
🇺🇸Clinical Trials group at the Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02432690
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT02432326
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸Northwest Cancer Specialists, PC, Vancouver, Washington, United States
Dasotraline Pediatric ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02428088
- Locations
- 🇺🇸
Gulfcoast Clinical Research, Fort Myers, Florida, United States
🇺🇸Neurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02352558
- Locations
- 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸West Clinic, Germantown, Tennessee, United States
🇺🇸Northwest Cancer Specialists, PC, Vancouver, Washington, United States
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02315534
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT02279719
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States
Dasotraline Adult ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT02276209
- Locations
- 🇺🇸
Gulfcoast Clinical Research, Fort Myers, Florida, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States